Nyxoah Genio hits both pivotal endpoints in sleep apnea patients excluded from current U.S. neurostimulation
Nyxoah’s ACCCESS pivotal study produced a 77.2% AHI responder rate and 87.7% oxygen-desaturation responder rate with no device-related serious adverse events through 12 months.